Clinical data | |
---|---|
Trade names | ExEm Foam |
License data | |
Pregnancy category |
|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
UNII |
Air polymer-type A, sold under the brand name ExEm Foam, is a drug for the detection of fallopian tube patency (openness) in people with known or suspected infertility.[1][2] It was approved for use in the United States in November 2019.[2][3]
Air polymer-type A is infused into the uterus to allow for visual assessment of fallopian tubes during an ultrasound examination called a sonohysterosalpingography.[2]
The most common adverse reactions are pelvic pain and abdominal pain, nausea and faintness (caused by a nerve and blood vessel reaction called vasovagal reaction) and post-procedure spotting.[2]
The US Food and Drug Administration (FDA) approved air polymer-type A based on literature reports.[2] To evaluate how well air polymer-type A works, the FDA primarily used data from two trials.[2] Trial A[4] was conducted at a site in Italy and Trial B[5] at three sites in Poland.[2]
Evaluation of side effects was based on multiple literature reports and collected safety reports from countries where air polymer-type A is already approved.[2]
((cite journal))
: CS1 maint: overridden setting (link)